Skip to main content
NRXP
NASDAQ Life Sciences

NRx Posts $2.2M Q3 Loss as First Ketamine Launch Begins

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$2.1
Mkt Cap
$93.839M
52W Low
$1.62
52W High
$5.055
52W Position info
30% above low
Off High info
58% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

NRXP sits 30% above its 52-week low of $1.62.

Summary

NRx reported a Q3 2026 net loss of $2.2 million, or $0.05 per share, versus $5.9 million, or $0.27 per share, a year earlier, with net patient service revenue of $1.2 million from its HOPE Therapeutics clinics. The company ended September with $19.8 million in cash and no convertible debt, following a June 2026 public offering that raised roughly $22.3 million gross. The bigger story is the commercial transition: after the October 30 FDA approval of preservative-free ketamine, a 17-person sales force is in the field, the first order is in hand, and shipments are scheduled to begin no later than January 2027. Management also disclosed a Yale collaboration supporting the Accelerated Approval pathway for NRX-100, a new subcutaneous pipeline product NRX-200, and an $11.25 million DARPA prime contract with the first two invoices approved for Q4 payment. Operating loss widened to $8.1 million from $4.0 million on launch preparation costs, so the cash balance and the pace of the ketamine rollout are the key variables. The company targets a rolling NDA submission for NRX-100 by the end of 2026.

At the time of this announcement, NRXP was trading at $2.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $93.8M. The 52-week trading range was $1.62 to $5.06. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

NRXP - Latest Insights

NRXP
Oct 30, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $2.98
Real-time Price: $2.22 info
Change: -$0.7624 (-26%) info
Market Cap: $93.839M info
NRXP
Oct 15, 2026, 8:27 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $2.55
Real-time Price: $2.22 info
Change: -$0.3326 (-13%) info
Market Cap: $93.839M info
NRXP
Oct 05, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.86
Real-time Price: $2.22 info
Change: -$0.6426 (-22%) info
Market Cap: $93.839M info
NRXP
Sep 30, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.98
Real-time Price: $2.22 info
Change: -$0.7671 (-26%) info
Market Cap: $93.839M info
NRXP
Sep 15, 2026, 9:17 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.35
Real-time Price: $2.22 info
Change: -$1.13 (-34%) info
Market Cap: $93.839M info